|1.||Green, B A: 2 articles (06/2001 - 06/2000)|
|2.||Zhu, Duzhang: 1 article (01/2003)|
|3.||Shroff, Khushroo E: 1 article (01/2003)|
|4.||DeBruin, Sylvia: 1 article (01/2003)|
|5.||Zamb, Timothy J: 1 article (01/2003)|
|6.||Periwal, Sangeeta B: 1 article (01/2003)|
|7.||Kourie, Kristin R: 1 article (01/2003)|
|8.||Eldridge, John H: 1 article (01/2003)|
|9.||Blakeney, Susan J: 1 article (01/2003)|
|10.||Smith, Larry: 1 article (01/2003)|
01/17/2003 - "A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine."
01/01/2001 - "CT-E29H has been shown to maintain the adjuvant effect of parental cholera holotoxin. "
06/01/2000 - "Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H."
06/01/2001 - "Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain. "
|2.||monophosphoryl lipid A